透析与肾移植患者对SARS-CoV-2感染和疫苗的免疫反应
本文总结了维持性透析和肾移植患者对COVID-19感染免疫的持久性及对疫苗的应答。初步数据显示感染后免疫持久,首剂疫苗应答低于健康人,第二剂后透析患者多数产生强抗体滴度,而肾移植患者应答较弱。
要点
- 透析和肾移植患者感染COVID-19后免疫反应具有持久性
- 首剂疫苗后感染未暴露患者抗体应答低于健康人
- 第二剂后透析患者多产生强抗体滴度,肾移植患者应答较弱
核心结论
- 透析和肾移植患者感染SARS-CoV-2后免疫反应具有持久性
- 两组合并感染未暴露患者首剂疫苗应答低于健康人
- 第二剂后透析患者多产生强抗体滴度,肾移植患者应答较弱
主要发现
- 感染后免疫反应具有持久性
- 首剂疫苗后感染未暴露患者抗体应答低于健康人
- 第二剂后维持性透析患者中相当部分产生强抗体滴度
- 肾移植受者疫苗免疫应答较弱
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this issue of Kidney International, the initial experience regarding the immunogenicity of prior coronavirus disease 2019 (COVID-19) infection and the response to the COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients is summarized. Preliminary data suggest that there is durability of immune response after COVID-19 infection. Although immune response to the first dose of vaccine is less in infection-naïve patients than healthy individuals in both groups, after the second vaccine dose a significant portion of patients receiving maintenance dialysis develop robust antibody titers, whereas kidney transplant recipients show a less-strong immune response.
引用
- Ikizler TA, Coates PT, Rovin BH, et al. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. 2021. PMID: 33931226. doi:10.1016/j.kint.2021.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。